Teva Pharmaceutical Industries (NYSE:TEVA) Updates FY 2025 Earnings Guidance

Teva Pharmaceutical Industries (NYSE:TEVA) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided earnings per share guidance of 2.350-2.650 for the period, compared to the consensus earnings per share estimate of 2.540. The company issued revenue guidance of $16.8 billion-$17.4 billion, compared to the consensus revenue estimate of $17.1 billion. Teva Pharmaceutical Industries also updated its Q1 2025 guidance to 0.520-0.520 EPS.

Analyst Ratings Changes

Several equities research analysts have commented on TEVA shares. StockNews.com downgraded Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Thursday. UBS Group dropped their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Piper Sandler increased their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. Barclays decreased their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. Finally, Bank of America dropped their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, March 6th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $23.43.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE:TEVA opened at $15.06 on Friday. The firm’s 50 day simple moving average is $17.21 and its two-hundred day simple moving average is $18.12. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The company has a market capitalization of $17.07 billion, a P/E ratio of -10.38, a P/E/G ratio of 1.44 and a beta of 0.82. Teva Pharmaceutical Industries has a 1-year low of $12.51 and a 1-year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Research analysts expect that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.